GlobalData
2 min read
Piramal Pharma Solutions has announced an investment of $90m to expand its two US facilities, enhancing manufacturing capabilities for sterile injectables and antibody-drug conjugate (ADC) therapies.
A ground-breaking ceremony was held on 25 June 2025 to mark the commencement of work on Lexington's site expansion.
The company’s Riverview, Michigan site is expected to be operational by the end of 2025 and will undergo an enhancement that includes adding a commercial scale suite designed specifically for high potency APIs (HPAPIs).
The Riverview facility will also provide payload-linkers, which are crucial for the safety and efficacy of ADC therapies, under the company's ADCelerate programme.
In Lexington, Kentucky, Piramal Pharma is increasing its fill/finish facility with an additional 24,000ft² of manufacturing space.
The expansion will introduce a new laboratory and advanced machinery such as a new filling line, two large size lyophilisers, a capping machine and an external vial washer.
The expansion will be concluded by late 2027, with production capacity increasing from 104 batches annually at peak utilisation to more than 240 batches.
Piramal Global Pharma CEO Peter DeYoung stated: “ADCs are rapidly emerging as one of the most effective classes of precision immunotherapy targeting certain cancers and tumours.
“As this class of drugs becomes more prevalent, we will adapt our services to accommodate this growing demand. By investing in the Lexington and Riverview facilities, we will enhance our integrated ADC offering, ADCelerate, and increase our capacity to bring high-quality, innovative treatments to our clients and their patients worldwide.”
The expansions come amid surging market growth for sterile injectables due to increased medical needs, regulatory approvals and scientific progress.
ADC therapies are witnessing high interest due to their efficacy and wider acceptance among healthcare regulators. The investment at the Lexington site goes beyond capacity building but also contributes to 40 new permanent positions.
"Piramal Pharma announces $90m investment to expand US sites" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
